178 related articles for article (PubMed ID: 37944087)
21. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.
Liu X; Qin S
Oncologist; 2019 Feb; 24(Suppl 1):S3-S10. PubMed ID: 30819826
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
23. Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study.
Zhang Y; Fan W; Wang Y; Huang G; Li J
Cancer Control; 2019; 26(1):1073274819872216. PubMed ID: 31466465
[TBL] [Abstract][Full Text] [Related]
24. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
Casadei-Gardini A; Rimassa L; Rimini M; Yoo C; Ryoo BY; Lonardi S; Masi G; Kim HD; Vivaldi C; Ryu MH; Rizzato MD; Salani F; Bang Y; Pellino A; Catanese S; Burgio V; Cascinu S; Cucchetti A
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3665-3671. PubMed ID: 33745079
[TBL] [Abstract][Full Text] [Related]
25. Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West.
Yen YH; Cheng YF; Wang JH; Lin CC; Chen YY; Yong CC; Liu YW; Cheng JY; Chen CH; Hu TH
PLoS One; 2020; 15(3):e0230005. PubMed ID: 32163475
[TBL] [Abstract][Full Text] [Related]
26. Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma.
Piñero F; Tanno M; Aballay Soteras G; Tisi Baña M; Dirchwolf M; Fassio E; Ruf A; Mengarelli S; Borzi S; Fernández N; Ridruejo E; Descalzi V; Anders M; Mazzolini G; Reggiardo V; Marciano S; Perazzo F; Spina JC; McCormack L; Maraschio M; Lagues C; Gadano A; Villamil F; Silva M; Cairo F; Ameigeiras B;
Ann Hepatol; 2020; 19(5):546-569. PubMed ID: 32593747
[TBL] [Abstract][Full Text] [Related]
27. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G;
Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229
[TBL] [Abstract][Full Text] [Related]
28. A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007-2015.
Huang CC; Chen HY; Chang RH; Liao PA; Lien HH; Hung CS; Yang SS; Hu JT
Drug Des Devel Ther; 2019; 13():397-404. PubMed ID: 30774305
[TBL] [Abstract][Full Text] [Related]
29. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
Singal AG; Lim JK; Kanwal F
Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib use in hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma: A propensity score matching study.
Lee YC; Wang JH; Chen CH; Hung CH; Lo KC; Yen YH; Kee KM; Hu TH; Lu SN; Kuo YH
Kaohsiung J Med Sci; 2021 Oct; 37(10):894-902. PubMed ID: 34166565
[TBL] [Abstract][Full Text] [Related]
31. Treatment options after sorafenib failure in patients with hepatocellular carcinoma.
Dika IE; Abou-Alfa GK
Clin Mol Hepatol; 2017 Dec; 23(4):273-279. PubMed ID: 29151326
[TBL] [Abstract][Full Text] [Related]
32. Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies.
Liu PH; Huo TI; Miksad RA
Semin Liver Dis; 2018 Aug; 38(3):242-251. PubMed ID: 30041276
[TBL] [Abstract][Full Text] [Related]
33. Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.
Hsu PY; Hsu CT; Yeh ML; Huang CF; Huang CI; Liang PC; Lin YH; Hsieh MY; Wei YJ; Hsieh MH; Dai CY; Lin ZY; Chen SC; Huang JF; Yu ML; Chuang WL
Dig Dis Sci; 2020 Jul; 65(7):2120-2129. PubMed ID: 31722058
[TBL] [Abstract][Full Text] [Related]
34. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
35. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
[TBL] [Abstract][Full Text] [Related]
36. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium.
Yang JD; Mohamed EA; Aziz AO; Shousha HI; Hashem MB; Nabeel MM; Abdelmaksoud AH; Elbaz TM; Afihene MY; Duduyemi BM; Ayawin JP; Gyedu A; Lohouès-Kouacou MJ; Ndam AW; Moustafa EF; Hassany SM; Moussa AM; Ugiagbe RA; Omuemu CE; Anthony R; Palmer D; Nyanga AF; Malu AO; Obekpa S; Abdo AE; Siddig AI; Mudawi HM; Okonkwo U; Kooffreh-Ada M; Awuku YA; Nartey YA; Abbew ET; Awuku NA; Otegbayo JA; Akande KO; Desalegn HM; Omonisi AE; Ajayi AO; Okeke EN; Duguru MJ; Davwar PM; Okorie MC; Mustapha S; Debes JD; Ocama P; Lesi OA; Odeghe E; Bello R; Onyekwere C; Ekere F; Igetei R; Mah'moud MA; Addissie B; Ali HM; Gores GJ; Topazian MD; Roberts LR;
Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):103-111. PubMed ID: 28403980
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.
Li J; Hou Y; Cai XB; Liu B
World J Gastroenterol; 2016 Apr; 22(15):4034-40. PubMed ID: 27099447
[TBL] [Abstract][Full Text] [Related]
38. Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.
Roccarina D; Majumdar A; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011649. PubMed ID: 28281295
[TBL] [Abstract][Full Text] [Related]
39. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
Shek D; Read SA; Nagrial A; Carlino MS; Gao B; George J; Ahlenstiel G
Oncologist; 2021 Jul; 26(7):e1216-e1225. PubMed ID: 33818870
[TBL] [Abstract][Full Text] [Related]
40. Hepatocellular carcinoma in sub-Saharan (tropical) Africa.
Balint GA; Ghebrekidan H; Balint E
Acta Med Hung; 1991; 48(3-4):177-87. PubMed ID: 1668371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
